Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade.
作者信息
Dunn Ian F, Du Ziming, Touat Mehdi, Sisti Michael B, Wen Patrick Y, Umeton Renato, Dubuc Adrian M, Ducar Matthew, Canoll Peter D, Severson Eric, Elvin Julia A, Ramkissoon Shakti H, Lin Jia-Ren, Cabrera Lais, Acevedo Brenda, Sorger Peter K, Ligon Keith L, Santagata Sandro, Reardon David A
机构信息
Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA.
Department of Pathology, Brigham and Women's Hospital, Boston, MA.
出版信息
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00190. Epub 2018 Nov 27.
Abstract
摘要
相似文献
1
Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade.高级别脑膜瘤中的错配修复缺陷：一种罕见但反复出现的事件，与显著的免疫激活及对PD-1阻断的临床反应相关。
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00190. Epub 2018 Nov 27.
2
Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics.膀胱原发性腺癌缺乏错配修复缺陷，并在肿瘤浸润免疫细胞中表现出 PD-L1 表达，这对诊断和治疗都有影响。
Hum Pathol. 2019 Dec;94:58-63. doi: 10.1016/j.humpath.2019.10.005. Epub 2019 Oct 27.
3
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.错配修复缺陷与免疫检查点阻断反应
Oncologist. 2016 Oct;21(10):1200-1211. doi: 10.1634/theoncologist.2016-0046. Epub 2016 Jul 13.
4
Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report.舒尼替尼治疗复发性非典型脑膜瘤引起脑脊液鼻漏的戏剧性放射学反应：病例报告。
J Neurosurg. 2017 Nov;127(5):965-970. doi: 10.3171/2016.9.JNS161629. Epub 2016 Dec 9.
5
Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.全面分析 PD-L1 表达、HER2 扩增、ALK/EML4 融合以及错配修复缺陷作为卵巢癌潜在的预测和预后因素。
Virchows Arch. 2019 May;474(5):599-608. doi: 10.1007/s00428-019-02528-6. Epub 2019 Feb 7.
6
Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.错配修复缺陷型结直肠癌：尽管肿瘤细胞中程序性细胞死亡配体 1 的表达无显著意义，但仍是一种免疫原性和免疫细胞丰富的肿瘤模型。
Hum Pathol. 2018 Feb;72:135-143. doi: 10.1016/j.humpath.2017.09.019. Epub 2017 Dec 5.
7
Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.儿童难治性胶质母细胞瘤伴胚系双等位基因错配修复缺陷患者对纳武利尤单抗的持久应答。
Oncologist. 2018 Dec;23(12):1401-1406. doi: 10.1634/theoncologist.2018-0163. Epub 2018 Aug 13.
8
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.间变性脑膜瘤中免疫调节分子PD-L1（CD274）表达增加。
Oncotarget. 2015 Mar 10;6(7):4704-16. doi: 10.18632/oncotarget.3082.
9
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.两名接受抗 PD-1 治疗获益患者中持久的突变型致癌基因特异性 T 细胞。
J Immunother Cancer. 2019 Feb 11;7(1):40. doi: 10.1186/s40425-018-0492-x.
10
Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.肿瘤类型间程序性死亡配体1（PD-L1）表达、错配修复缺陷与预后的相关性：对免疫治疗的意义
Oncotarget. 2017 Aug 24;8(44):77415-77423. doi: 10.18632/oncotarget.20492. eCollection 2017 Sep 29.
引用本文的文献
1
Biomarkers of immunotherapy response in neuro-oncology.神经肿瘤学中免疫治疗反应的生物标志物。
Neurooncol Adv. 2025 Sep 9;7(Suppl 4):iv32-iv40. doi: 10.1093/noajnl/vdaf104. eCollection 2025 Sep.
2
Recurrent TRAF7-mutated meningioma: Molecular evolution and therapeutic insights.复发性TRAF7突变型脑膜瘤：分子进化与治疗见解
SAGE Open Med Case Rep. 2025 Aug 3;13:2050313X251363340. doi: 10.1177/2050313X251363340. eCollection 2025.
3
Case report: Clonal evolution analysis of a rare case of meningioma lung metastases identifies actionable alterations in matched longitudinal tumour samples.病例报告：一例罕见的脑膜瘤肺转移病例的克隆进化分析确定了匹配的纵向肿瘤样本中的可操作改变。
Front Oncol. 2025 Jan 28;14:1483126. doi: 10.3389/fonc.2024.1483126. eCollection 2024.
4
A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumor.一项关于帕博利珠单抗用于复发性脑膜瘤和孤立性纤维瘤的II期开放标签单臂试验。
Neurooncol Adv. 2024 Sep 16;6(1):vdae154. doi: 10.1093/noajnl/vdae154. eCollection 2024 Jan-Dec.
5
Cancer stem cells in meningiomas: novel insights and therapeutic implications.脑膜瘤中的癌症干细胞：新见解与治疗意义
Clin Transl Oncol. 2025 Apr;27(4):1438-1459. doi: 10.1007/s12094-024-03728-6. Epub 2024 Sep 24.
6
Investigation of the status of immune checkpoint molecules (PD-L1 and PD-1) in meningiomas by immunohistochemistry.免疫检查点分子（PD-L1 和 PD-1）在脑膜瘤中的免疫组织化学研究。
Turk J Med Sci. 2024 Apr 2;54(4):735-743. doi: 10.55730/1300-0144.5843. eCollection 2024.
7
Response to immune checkpoint inhibition in a meningioma with DNA mismatch repair deficiency.DNA错配修复缺陷的脑膜瘤对免疫检查点抑制的反应
Neurooncol Adv. 2024 Jun 8;6(1):vdae092. doi: 10.1093/noajnl/vdae092. eCollection 2024 Jan-Dec.
8
Evolving concepts in meningioma management in the era of genomics.在基因组学时代，脑膜瘤管理的概念不断发展。
Cancer. 2024 Aug 1;130(15):2586-2600. doi: 10.1002/cncr.35279. Epub 2024 May 16.
9
Novel Advances in Treatment of Meningiomas: Prognostic and Therapeutic Implications.脑膜瘤治疗的新进展：预后及治疗意义
Cancers (Basel). 2023 Sep 12;15(18):4521. doi: 10.3390/cancers15184521.
10
The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors.免疫疗法在治疗罕见中枢神经系统肿瘤中的作用。
Curr Oncol. 2023 May 25;30(6):5279-5298. doi: 10.3390/curroncol30060401.
本文引用的文献
1
DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome.DMD 基因组缺失是具有不良预后的进行性/高级别脑膜瘤的一个亚组特征。
Acta Neuropathol. 2018 Nov;136(5):779-792. doi: 10.1007/s00401-018-1899-7. Epub 2018 Aug 19.
2
Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes.使用 t-CyCIF 和传统光学显微镜对人组织和肿瘤进行高多重免疫荧光成像。
Elife. 2018 Jul 11;7:e31657. doi: 10.7554/eLife.31657.
3
Meningioma transcription factors link cell lineage with systemic metabolic cues.脑膜瘤转录因子将细胞谱系与全身代谢线索联系起来。
Neuro Oncol. 2018 Sep 3;20(10):1331-1343. doi: 10.1093/neuonc/noy057.
4
Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.多重免疫荧光揭示颅咽管瘤中潜在的 PD-1/PD-L1 通路脆弱性。
Neuro Oncol. 2018 Jul 5;20(8):1101-1112. doi: 10.1093/neuonc/noy035.
5
Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.程序性死亡配体 1 表达和肿瘤浸润淋巴细胞在神经纤维瘤病 1 型和 2 型相关肿瘤中的表达。
J Neurooncol. 2018 May;138(1):183-190. doi: 10.1007/s11060-018-2788-6. Epub 2018 Feb 9.
6
De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.原发性和继发性间变性脑膜瘤：临床和组织分子预后因素研究。
Neuro Oncol. 2018 Jul 5;20(8):1113-1121. doi: 10.1093/neuonc/nox231.
7
Progestin-associated shift of meningioma mutational landscape.孕激素相关脑膜瘤突变特征谱改变。
Ann Oncol. 2018 Mar 1;29(3):681-686. doi: 10.1093/annonc/mdx763.
8
Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis.胚系 SUFU 突变携带者与髓母细胞瘤：临床特征、癌症风险和预后。
Neuro Oncol. 2018 Jul 5;20(8):1122-1132. doi: 10.1093/neuonc/nox228.
9
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.DNA 修复失活会引发新抗原生成，并损害肿瘤生长。
Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673. Epub 2017 Nov 29.
10
Comprehensive Analysis of Hypermutation in Human Cancer.人类癌症中高突变的综合分析。
Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub 2017 Oct 19.
Zotero 插件